UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Myriad Genetics (NASDAQ: MYGN) has announced its participation in the 43rd Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's President and CEO Paul J. Diaz, along with COO Sam Raha, will deliver a presentation on Wednesday, January 15, at 3:45 PM PT (6:45 PM ET).
Investors and interested parties can access the presentation through a live webcast available in the investor relations section of Myriad's website at investor.myriad.com. An archived version of the presentation will be made available following the live event.
Details
News Market Reaction – MYGN
The recorded move for MYGN in the trading session of this news was +3.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
News release updated to include the members of the management team speaking at the conference.
SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET).
The presentation will be available through a live webcast in the investor relations section of Myriad’s website at investor.myriad.com. An archived edition of the presentation will be available later that day.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.